Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Teva announces top-line results from GALA Phase III trial evaluating a new dosage for glatiramer acetate given three times weekly for relapsing-remitting multiple sclerosis
Impact of MS during the critical window of brain development.
Molecular mechanism underlying the impact of vitamin D on disease activity of MS.
Complexity of trophic factor signaling in experimental autoimmune encephalomyelitis: Differential expression of neurotrophic and gliotrophic factors.
New approaches in the management of multiple sclerosis.
Biogen Idec's long-acting beta interferon moves ahead in MS
US court permits generic version of Teva MS drug a year sooner
Trimesta in relapsing-remitting multiple sclerosis patients (Phase II)
Rituximab, an anti-CD20 monoclonal antibody: History & mechanism: Off label rituximab use in transplant patients
A novel pH-sensitive interferon-β (INF-β) oral delivery system for application in multiple sclerosis.
Phase 3 Study of RPC1063 in Relapsing MS
Teriflunomide (Aubagio) approved for use by the NHS in Scotland and Northern Ireland
The Effect of Glatiramer Acetate Therapy on Functional Properties of B Cells From Patients With Relapsing-Remitting Multiple Sclerosis.
Cognitive impairment in multiple sclerosis.
Pharmacokinetics of CAMPATH-1H in BMT patients.
Claudin-1 induced sealing of blood-brain barrier tight junctions ameliorates chronic experimental autoimmune encephalomyelitis.
NQO1-dependent redox cycling of idebenone: effects on cellular redox potential and energy levels.
FDA approval letter for daclizumab for the prophylaxis of acute organ rejection in patients receiving renal transplants
Pathway and network-based analysis of genome-wide association studies in multiple sclerosis.
Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone.
ExtaviJect® 30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European study.
Impact of cladribine therapy on changes in circulating dendritic cell subsets, T cells and B cells in patients with multiple sclerosis.
Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases.
The topograpy of demyelination and neurodegeneration in the multiple sclerosis brain.
UCSF Neuroimmunology Seminar

Pages